Marie Montus

1.9k total citations · 1 hit paper
10 papers, 1.1k citations indexed

About

Marie Montus is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Marie Montus has authored 10 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Genetics and 2 papers in Oncology. Recurrent topics in Marie Montus's work include Muscle Physiology and Disorders (6 papers), Virus-based gene therapy research (5 papers) and CAR-T cell therapy research (2 papers). Marie Montus is often cited by papers focused on Muscle Physiology and Disorders (6 papers), Virus-based gene therapy research (5 papers) and CAR-T cell therapy research (2 papers). Marie Montus collaborates with scholars based in France, United Kingdom and Italy. Marie Montus's co-authors include Carole Masurier, P. Véron, Christian Leborgne, Olivier Benvéniste, Sylvie Boutin, Laurent Servais, Sabine Charrier, Thomas Voit, Fatima Amor and Jérôme Poupiot and has published in prestigious journals such as PLoS ONE, Human Molecular Genetics and Investigative Ophthalmology & Visual Science.

In The Last Decade

Marie Montus

9 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

2010 753 citations Sylvie Boutin, P. Véron et al. Human Gene Therapy profile →

Peers

Countries citing papers authored by Marie Montus

Since Specialization

Citations

This map shows the geographic impact of Marie Montus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Montus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Montus more than expected).

Fields of papers citing papers by Marie Montus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Montus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Montus. The network helps show where Marie Montus may publish in the future.

Co-authorship network of co-authors of Marie Montus

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Montus. A scholar is included among the top collaborators of Marie Montus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Montus. Marie Montus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy 2020 ·Molecular Therapy — Methods & Clinical Development ·Virginie Mariot, Caroline Le Guiner, Inès Barthélémy, Marie Montus, Stéphane Blot, Silvia Torelli, Jennifer E. Morgan, Francesco Muntoni, Thomas Voit, Julie Dumonceaux	16
2	An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress 2019 ·Molecular Therapy — Methods & Clinical Development ·David Israeli, Jérémie Cosette, Guillaume Corre, Fatima Amor, Jérôme Poupiot, Daniel Stockholm, Marie Montus, Bernard Gjata, Isabelle Richard	21
3	RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect 2017 ·Molecular Therapy — Nucleic Acids ·Claire Domenger, (unknown), Virginie François, Adrien Léger, (unknown), Marie Montus, Laurent Servais, Thomas Voit, Philippe Moullier, Yann Audic, Caroline Le Guiner	7
4	Dystrophin Threshold Level Necessary for Normalization of Neuronal Nitric Oxide Synthase, Inducible Nitric Oxide Synthase, and Ryanodine Receptor-Calcium Release Channel Type 1 Nitrosylation in Golden Retriever Muscular Dystrophy Dystrophinopathy 2016 ·Human Gene Therapy ·Christel Gentil, Caroline Le Guiner, Sestina Falcone, Jean‐Yves Hogrel, Cécile Peccate, Stéphanie Lorain, Sofia Benkhelifa‐Ziyyat, Lydie Guigand, Marie Montus, Laurent Servais, Thomas Voit, France Piétri‐Rouxel	11
5	Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy 2015 ·NMR in Biomedicine ·Claire Wary, Noura Azzabou, Céline Giraudeau, (unknown), Marie Montus, Thomas Voït, Laurent Servais, Pierre G. Carlier	57
6	Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON) 2014 ·Investigative Ophthalmology & Visual Science ·Nitza Thomasson, Hélène Cwerman‐Thibault, Sébastien Augustin, (unknown), José‐Alain Sahel, Didier Pruneau, Marie Montus, Anne Galy, Marisol Corral‐Debrinski	1
7	Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies 2013 ·PLoS ONE ·Nicolas Vignier, Fatima Amor, Paul Fogel, (unknown), Jérôme Poupiot, Sabine Charrier, Michel Arock, Marie Montus, Isabelle Nelson, Isabelle Richard, Lucie Carrier, Laurent Servais, Thomas Voit, Gisèle Bonne, David Israeli	89
8	Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors breakdown → 2010 ·Human Gene Therapy ·Sylvie Boutin, (unknown), P. Véron, Christian Leborgne, Olivier Benvéniste, Marie Montus, Carole Masurier	753
9	Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott–Aldrich Syndrome in Preclinical Models 2009 ·Molecular Therapy ·Francesco Marangoni, Marita Bosticardo, Sabine Charrier, Elena Draghici, Michela Locci, Samantha Scaramuzza, Cristina Panaroni, Maurilio Ponzoni, Francesca Sanvito, Claudio Doglioni, (unknown), Bernard Gjata, Marie Montus, Katherine A. Siminovitch, Alessandro Aiuti, Luigi Naldini, Loı̈c Dupré, Maria Grazia Roncarolo, Anne Galy, Anna Villa	64
10	AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis 2008 ·Human Molecular Genetics ·Anna Buj‐Bello, Françoise Fougerousse, Yannick Schwab, Nadia Messaddeq, Danièle Spehner, Christopher R. Pierson, Muriel Durand, Christine Kretz, Olivier Danos, Anne‐Marie Douar, Alan H. Beggs, Patrick Schultz, Marie Montus, Patrice Denèfle, Jean‐Louis Mandel	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact